Genmab A/S

355 articles with Genmab A/S

• 

  Genmab Raises $506 Million in IPO

  7/18/2019

  Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.

• Genedata Biopharma Platform Adopted by Genmab to Streamline Biotherapeutics R&D Operations

  7/9/2019

  Genedata E2E software solution to increase speed and efficiency of discovery and development of Genmab’s next-generation cancer therapies

• 

  Another Win For Darzalex as FDA Approves Combination Treatment For Multiple Myeloma

  6/28/2019

  Darzalex in combination with lenalidomide and dexamethasone was approved as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant.
• 

  Genmab and Janssen Team Up to Develop Next-Generation CD38 Antibody

  6/11/2019

  The agreement is the outcome of preclinical research on novel CD38 targeting concepts conducted by Genmab.
• 

  Already Public in Denmark, Genmab Files for $500 Million IPO in the U.S.

  5/29/2019

  The company’s board of directors hasn’t made a final decision to proceed with the listing.
• 

  FDA Approves J&J and GenMab’s Split-Dosing Regimen for Darzalex

  2/12/2019

  Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.

• MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab

  1/31/2019

  MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.

• Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab

  1/29/2019

  MorphoSys AG announces that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746, 9,200,061 and 9,758,590 are invalid.

• 

  Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

  11/30/2018

  The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
• 

  Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial

  10/30/2018

  Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).

• Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress

  10/8/2018

  Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer

• 

  BioNTech Inks $425 Million Collaboration Deal with Pfizer to Develop mRNA-based Flu Vaccines

  8/16/2018

  BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.

• Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors

  7/12/2018

  Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial.

• 

  Genmab and Immatics Partner on Next-Generation T-Cell Bispecific Immunotherapies Program

  7/12/2018

  Denmark-based Genmab A/S struck a discovery and development deal with Immatics Biotechnologies GmbH.

• Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies

  7/12/2018

  Immatics Biotechnologies GmbH, announced today that it has entered into a research collaboration and license agreement with Genmab A/S (Nasdaq Copenhagen: GEN).

• 

  Genmab and Johnson & Johnson Halt Lung Cancer Study

  5/29/2018

  Genmab A/S, and Johnson & Johnson’s Janssen division have pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq.

• Genmab Announces 2017 Net Sales Figures for DARZALEX (Daratumumab)

  1/23/2018

  Net sales of DARZALEX in 2017 totaled USD 1,242 million.

• U.S. FDA Grants Priority Review for Genmab's Daratumumab in Front Line Multiple Myeloma

  1/22/2018

  The sBLA was submitted by Genmab’s licensing partner, Janssen Biotech, Inc., in November 2017.

• Genmab Announces Novartis’ Intention to Transition Arzerra (ofatumumab) From Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-U.S. Markets

  1/22/2018

  As a consequence, Novartis will pay Genmab a lump sum of USD 50 million as payment for lost potential milestones and royalties.

• Genmab: Major Shareholder Announcement - Jan. 10, 2018

  1/10/2018

  As of January 5, 2018, Artisan Partners Limited Partnership has increased their indirect ownership in Genmab A/S to 3,081,731 shares.